Johnson & Johnson Highlights Pharmaceutical Growth Strategies and Robust Pipeline to Address Unmet Medical Needs

 Johnson & Johnson Highlights Pharmaceutical Growth Strategies and Robust Pipeline to Address Unmet Medical Needs

* * *
Early stage compounds and new filings targeted in five therapeutic areas
* * *
Expanding indications for strong core products builds "pipeline in a product"
* * *
Leveraging global capabilities and reach drives growth efforts in emerging markets
* * *
Biomarkers and diagnostics combine with therapies to advance personalized medicine
* * *
Company's vision focuses on improving human health and reducing global burden of disease


New Brunswick, N.J. (June 4, 2009) - Johnson & Johnson will be reviewing the growth strategies and pipeline for its Pharmaceutical business at a meeting with the investment community today.  Senior leaders from the company's pharmaceutical segment will outline how continued expansion of its core products, progress in its pipeline, and an end-to-end approach to its research and development (R&D) will fuel its long-term growth and address unmet medical needs.

The company will highlight its plans for addressing these needs in five therapeutic areas:

  • Neuroscience - Johnson & Johnson is a leader in neuroscience, which not only includes central nervous system (CNS) disorders, but also treatment of pain - both acute and chronic. The company will continue to focus on its traditional areas of strength and high unmet need -- schizophrenia, epilepsy, bipolar disorder and pain -- while taking a different approach to neuroscience drug development, including greater emphasis in the future on cognition and dementia.
  • Cardiovascular disease and Metabolism - In this area, the company is focused on three major conditions -- cardiovascular disease, diabetes, and obesity - where incidence rates are soaring, placing a tremendous burden on patients as well as the global healthcare system.   This expanding portfolio is being built to address the growing need for new treatment options in this category.
  • Immunology -- In this area, the company's focus is on inflammation.  An estimated 50 million Americans suffer from diseases of the immune system, and there are approximately 10 million people living with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis and plaque psoriasis. 
  • Infectious Diseases - The company is extending its leadership in HIV and expanding into another virology market, hepatitis C.  Its portfolio in this area also includes broad-spectrum antibiotic drugs for the treatment of a wide range of infections.
  • Oncology - The company's strategy in oncology is focused on targeting both the tumor and tumor microenvironment, with an aim to prevent, treat, or cure cancer through a targeted approach to developing therapies.

Brief summaries of the therapeutic areas, products and compounds being discussed in today's presentations are available in this backgrounder: Pharmaceutical Segment Review Highlights.

 

Pharmaceutical Growth Strategies
Johnson & Johnson's pharmaceutical businesses generated $24.6 billion in sales last year, 39 percent of the company's total revenue, and ranks as the world's seventh largest pharmaceutical company and fourth largest biotech company.  Its portfolio includes nine products that delivered more than $1 billion in sales in 2008.  Its recent pace of regulatory filings, approvals and line extensions place it among the industry leaders and its robust pipeline positions it well for continued success.

"We are very optimistic about our future in pharmaceuticals," says Worldwide Chairman of Pharmaceuticals Sheri McCoy.  "We are well-positioned with an industry-leading pipeline, the global reach and financial resources of Johnson & Johnson, a long, rich history in pharmaceuticals, and a broad portfolio that is grounded in science and addresses serious unmet needs."  

With the pharmaceutical market at an estimated $750 billion globally, McCoy will outline five strategies for growth for the company's pharmaceutical businesses:

  • Grow the core global product portfolio - The company is focused on growing share in its core products (e.g., REMICADE®, RISPERDAL® CONSTA® and CONCERTA®) through greater market penetration, new commercial models and an expanded geographic presence.  Additionally, it will focus on lifecycle management of its products as exemplified by REMICADE, which is itself a "pipeline in a product" with 15 indications and ongoing clinical trials.
  • Successfully execute product launches - The company has several key products launching (e.g., SIMPONITM and NUCYNTATM) and has seven compounds filed and awaiting approvals.
  • Continue building a robust pipeline - The company is focused on the best science and actively pursues various sources of innovation (internal development, licensing, acquisitions and academic partnerships), which enable it to advance its work on specific diseases in five therapeutic areas.  Its capabilities in biomarkers and diagnostics distinguish the company as a leader in the future of personalized medicine.
  • Accelerate growth in emerging markets - With 95 percent of the world's patients and much of the growth in health care occurring outside the U.S., the company continues to use its global presence, decentralized operating model and productive relationships to serve local unmet medical needs around the world.
  •  Participate in dialogues shaping health care policy - Through its participation in global health care policy dialogues, the company is part of the effort to reduce the global burden of disease by driving greater efficiencies and increased access to affordable health care.

 

Fueling Growth Through Innovation
Paul Stoffels, M.D., global head of Research and Development for Pharmaceuticals, will report today on the business' recent track record of pipeline productivity and its long-term strategy for addressing some of the most important unmet medical needs in the world today. 

"Our pipeline productivity is on track.  In fact, 2008 was a year of significant submissions and approvals for us," says Stoffels.  "We had six new compounds approved in major markets, and we have seven compounds with filings pending in the U.S. and Europe.  We also had outstanding late-stage development progress, with five compounds advancing to late development.  And, finally, we expanded our portfolio through licensing, collaborations, and creating new partnerships in emerging regions such as India and China." 

Johnson & Johnson invested just over $5 billion in pharmaceutical R&D programs last year.  "Innovation and sustained R&D productivity are key to our long-term future," says Stoffels.  "The future drivers for success in pharmaceuticals will depend on matching the medical need with the best science and operational excellence.  It will require that we have a therapeutic area focus, an open innovation approach, an outcomes-based drug development strategy, broad-based expertise and global reach, and truly outstanding people."

The company is continuing to advance its pipeline of new compounds, while also exploring line extensions for existing drugs, which have the potential to become what the company calls a "pipeline in a product."  Among some of the early stage compounds being discussed today are the company's first compound for treating type 2 diabetes, the SGLT2 inhibitor, and CNTO-888, which has the potential for indications in both immunology and oncology.  Stoffels and other executives will discuss the company's expectations for new filings and early-stage compounds across each of the five therapeutic areas throughout the day.

"Our pipeline is robust and consists of compounds that are differentiated and meet unmet needs in global and large regional markets.  And our commercial teams around the world are working to deliver enhanced clinical and economic value," says McCoy.  "All of this together gives me great confidence in our ability to make a real difference in patients' lives."

Full copies of the presentations as well as a replay and podcast will be available approximately two hours after the live webcast concludes at www.investor.jnj.com. 

About Johnson & Johnson
Caring for the world, one person at a time ... inspires and unites the people of Johnson & Johnson. We embrace research and science -- bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 119,000 employees at more than 250 Johnson & Johnson companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

Suggested Articles

Henlius Biotech missed the $477 million goal it set for its IPO, but still made the top five biopharma IPOs this year with its $410 million listing.

Versantis will use the €16 million to trial a drug designed to remove toxic metabolites from liver disease patients.

The Merck-backed round positions Themis to take its chikungunya vaccine through phase 3 and start testing a cancer drug in humans.